Switch theme
Sign up to access all valuation multiples
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
1998
114
LTM Revenue $30.1M
LTM EBITDA -$26.7M
$117M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MaxCyte has a last 12-month revenue (LTM) of $30.1M and a last 12-month EBITDA of -$26.7M.
In the most recent fiscal year, MaxCyte achieved revenue of $51.9M and an EBITDA of -$62.3M.
MaxCyte expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MaxCyte valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $30.1M | XXX | $51.9M | XXX | XXX | XXX |
| Gross Profit | $25.1M | XXX | $42.3M | XXX | XXX | XXX |
| Gross Margin | 83% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | -$26.7M | XXX | -$62.3M | XXX | XXX | XXX |
| EBITDA Margin | -89% | XXX | -120% | XXX | XXX | XXX |
| EBIT | -$37.9M | XXX | -$68.8M | XXX | XXX | XXX |
| EBIT Margin | -126% | XXX | -133% | XXX | XXX | XXX |
| Net Profit | -$30.9M | XXX | -$55.1M | XXX | XXX | XXX |
| Net Margin | -103% | XXX | -106% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, MaxCyte's stock price is GBP 2 (or $2).
MaxCyte has current market cap of GBP 176M (or $236M), and EV of GBP 87.0M (or $117M).
See MaxCyte trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $117M | $236M | XXX | XXX | XXX | XXX | $-0.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, MaxCyte has market cap of $236M and EV of $117M.
MaxCyte's trades at 2.3x EV/Revenue multiple, and -1.9x EV/EBITDA.
Equity research analysts estimate MaxCyte's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MaxCyte has a P/E ratio of -5.7x.
See valuation multiples for MaxCyte and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $236M | XXX | $236M | XXX | XXX | XXX |
| EV (current) | $117M | XXX | $117M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | -3.3x | XXX | -1.9x | XXX | XXX | XXX |
| EV/EBIT | -2.3x | XXX | -1.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.7x | XXX | -4.3x | XXX | XXX | XXX |
| EV/FCF | -19.6x | XXX | -3.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMaxCyte's last 12 month revenue growth is 11%
MaxCyte's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $1.0M for the same period.
MaxCyte's rule of 40 is -96% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MaxCyte's rule of X is -62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MaxCyte and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | -2% | XXX | XXX | XXX |
| EBITDA Margin | -89% | XXX | -120% | XXX | XXX | XXX |
| EBITDA Growth | -12% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -96% | XXX | -110% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 69% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 214% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MaxCyte acquired XXX companies to date.
Last acquisition by MaxCyte was XXXXXXXX, XXXXX XXXXX XXXXXX . MaxCyte acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was MaxCyte founded? | MaxCyte was founded in 1998. |
| Where is MaxCyte headquartered? | MaxCyte is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does MaxCyte have? | As of today, MaxCyte has 114 employees. |
| Who is the CEO of MaxCyte? | MaxCyte's CEO is Mr. Maher Masoud. |
| Is MaxCyte publicy listed? | Yes, MaxCyte is a public company listed on LON. |
| What is the stock symbol of MaxCyte? | MaxCyte trades under MXCT ticker. |
| When did MaxCyte go public? | MaxCyte went public in 2016. |
| Who are competitors of MaxCyte? | Similar companies to MaxCyte include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of MaxCyte? | MaxCyte's current market cap is $236M |
| What is the current revenue of MaxCyte? | MaxCyte's last 12 months revenue is $30.1M. |
| What is the current revenue growth of MaxCyte? | MaxCyte revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of MaxCyte? | Current revenue multiple of MaxCyte is 2.9x. |
| Is MaxCyte profitable? | Yes, MaxCyte is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MaxCyte? | MaxCyte's last 12 months EBITDA is -$26.7M. |
| What is MaxCyte's EBITDA margin? | MaxCyte's last 12 months EBITDA margin is -89%. |
| What is the current EV/EBITDA multiple of MaxCyte? | Current EBITDA multiple of MaxCyte is -3.3x. |
| What is the current FCF of MaxCyte? | MaxCyte's last 12 months FCF is -$4.4M. |
| What is MaxCyte's FCF margin? | MaxCyte's last 12 months FCF margin is -15%. |
| What is the current EV/FCF multiple of MaxCyte? | Current FCF multiple of MaxCyte is -19.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
